\nThe funding supports activities into 2028 and will be used to expand and accelerate technical innovation with AI-powered portable MRI for neonatal scanning to conduct objective evaluation of neurodevelopment among infants and young children in resource-constrained settings. The UNITY project<\/a>, led by King\u2019s College London (King\u2019s), is using the accessible and scalable Swoop\u00ae system with a goal to ultimately enable more effective interventions that will improve child brain development and health globally.<\/p>\n \nMillions of infants worldwide are born prematurely, face malnutrition or experience other forms of health adversity, putting them at risk for delayed, impaired, or suboptimal neurodevelopment. To date, evaluation of neurodevelopment in resource-constrained countries has relied on proxy indicators, such as physical growth or behavioral tests, which may not accurately reflect brain development and prevent babies from receiving appropriate care. The Swoop\u00ae system offers a scalable, cost-effective solution for objectively assessing early brain development and monitoring the impact of maternal and child health interventions\u2014providing clinicians with real-time, actionable insights that can better inform treatment.<\/p>\n \n\u201cThrough our ongoing partnership with Hyperfine, we are now imaging the developing brain where it was once impossible,\u201d said Professor Steve Williams of King’s College London, principal investigator for the UNITY research initiative. \u201cThis collaboration will fill a critical role in providing a low-cost, scalable method for directly evaluating neurodevelopment\u2014ensuring more children have the chance not only to survive but thrive. Hyperfine brings all the relevant expertise needed for this investment to be successful. With the Swoop\u00ae system, we have already performed more than 10,000 examinations and scanned more than 6,000 babies and infants across five continents, demonstrating both the scalability and the life-changing potential of this technology.\u201d<\/p>\n \nThis grant supports further work through the UNITY project\u2014an initiative to study environmental influences on early brain maturation and the impact of malnutrition, infection, inflammation, and birth complications on neurodevelopment using portable MR imaging. This new phase takes the next step to focus on helping optimize treatment in underserved countries. The UNITY research initiative is composed of more than 40 academic and clinical centers across low-, middle-, and high-income countries, including Malawi, Ghana, Zambia, Kenya, India, and Pakistan.<\/p>\n \nWith this grant, the collaboration with King\u2019s aims to develop AI-based pipelines to improve image clarity and diagnostic reliability for neonatal patients, where motion and low signal-to-noise ratio present unique challenges. These targeted improvements are designed to deliver consistent and improved image quality for neonatal scanning that can advance Swoop\u00ae system use globally.<\/p>\n \n\u201cAs the company with the first FDA-cleared commercial ultra-low-field portable MR brain imaging system, Hyperfine remains uniquely positioned to lead and support this global effort,\u201d said Maria Sainz, President and CEO of Hyperfine, Inc. \u201cThis new grant reflects not only confidence in our technology, but also in our readiness to scale solutions that matter. We are proud to advance global health by making imaging technology more accessible in all parts of the world with the support from the Gates Foundation as we continue working with the UNITY project and its researchers on efforts that promote the healthy development of young children around the globe.\u201d<\/p>\n \nFor more information about the Swoop\u00ae AI-powered portable MRI system, visit HyperfineMRI.com<\/a>.<\/p>\n About the Swoop\u00ae Portable MRI Systems<\/b><\/p>\n \nThe Swoop\u00ae Portable MR Imaging\u00ae Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.<\/p>\n About Hyperfine, Inc.<\/b><\/p>\n \nHyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop\u00ae system\u2014the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop\u00ae system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit HyperfineMRI.com<\/a>.<\/p>\n \nThe Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc.<\/p>\n Forward-Looking Statements<\/b><\/p>\n \nThis press release includes \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the \u201cCompany\u201d) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as \u201cexpect,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cbudget,\u201d \u201cforecast,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cbelieves,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company\u2019s goals and commercial plans, the benefits of the Company\u2019s products and services, and the Company\u2019s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company\u2019s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company\u2019s product development and commercialization activities, including the degree that the Swoop\u00ae<\/i> system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company\u2019s business; the inability to maintain the listing of the Company\u2019s Class A common stock on the Nasdaq; the Company\u2019s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company\u2019s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company\u2019s products and services and reimbursement for medical procedures conducted using the Company\u2019s products and services; the Company\u2019s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company\u2019s financial performance; and other risks and uncertainties indicated from time to time in Company\u2019s filings with the Securities and Exchange Commission, including those under \u201cRisk Factors\u201d therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20251119948804\/en\/<\/a><\/span><\/p>\n Media Contact Investor Contact KEYWORDS:<\/b> Connecticut United States North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Women Radiology Children Baby\/Maternity Artificial Intelligence Mental Health Socially Responsible Investing Consumer Foundation Professional Services Philanthropy Technology Mobile\/Wireless FDA Biotechnology Neurology Health Health Technology<\/p>\n<\/p>\n
\n<\/b>
Devin Zell
\n
Hyperfine
\n
dzell@hyperfine.io<\/a><\/p>\n
\n<\/b>
Webb Campbell
\n
Gilmartin Group LLC
\n
webb@gilmartinir.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20251119948804\/en\/2375273\/3\/Hyperfine_Logomark_Full_Color_RGB_600px_tall.jpg\")
<\/td>\n<\/tr>\n